Study Assesses Acmopatide's Efficacy in Type 1 Diabetes with Obesity | Retatrutide News

A Phase 2 study is evaluating Acmopatide, a GLP-1/GIP receptor agonist, for Type 1 diabetes with obesity. The study's findings could influence future GL...
Clinical Trials · October 29, 2026